Literature DB >> 32220280

Tackling two pandemics: a plea on World Tuberculosis Day.

Tom Wingfield1, Luis E Cuevas2, Peter MacPherson3, Kerry A Millington4, S Bertel Squire5.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32220280      PMCID: PMC7118542          DOI: 10.1016/S2213-2600(20)30151-X

Source DB:  PubMed          Journal:  Lancet Respir Med        ISSN: 2213-2600            Impact factor:   30.700


× No keyword cloud information.
We are facing an unprecedented pandemic. A quarter of the world's population is infected and, between 2020 and 2021, it is predicted that 10 million people will have fallen ill, 3 million will not have been diagnosed or received care, and more than 1 million—mainly the most vulnerable—will have died. This pandemic is not COVID-19 but tuberculosis. On World Tuberculosis Day, it is worth comparing the COVID-19 and tuberculosis pandemics to ensure that, while we focus on the former, we do not forget the latter. A pandemic is defined as a disease that spreads across whole countries or the whole world. Tuberculosis and COVID-19 are both pandemics that show ongoing, sustained community transmission across continents. Indeed, no country is tuberculosis-free and this is likely to be the case soon for COVID-19. There are striking similarities between the two pandemics. Both cause major infection-related morbidity and mortality around the world. Tuberculosis was the leading cause of mortality from an infectious disease worldwide in 2018, causing 1·2 million deaths. COVID-19 has infected more than 300 000 people and caused over 13 000 deaths in the first quarter of 2020 alone. Both COVID-19 and tuberculosis can present with respiratory symptoms, and diagnosis and treatment of people with tuberculosis, or tuberculosis and COVID-19 co-infection, are likely to be compromised during the COVID-19 pandemic. Older people and those with comorbidities are at increased risk of severe disease and adverse outcomes in both diseases.3, 4 And, as we are discovering for COVID-19, both diseases have considerable social impact—including stigma, discrimination, and isolation—in addition to the economic impact from country productivity losses and catastrophic costs to individuals and households. There are also stark differences. While tuberculosis is a slow pandemic and has accompanied humankind for millennia, the coronavirus (SARS-CoV-2) that causes COVID-19 is new and spreading rapidly around the world. Tuberculosis has been labelled a pandemic many times over the past three centuries, whereas this is the first COVID-19 pandemic. Children are less severely affected by COVID-19, whereas 1·1 million children had tuberculosis disease in 2018, of whom 200 000 died. The vast majority of cases and deaths from tuberculosis occur in low-income and middle-income countries, whereas high-income countries have low rates. By contrast, Europe became the second epicentre of COVID-19 after China, which might explain, in part, why COVID-19 can be expected to mobilise more global resources and person-power in a year than tuberculosis has in decades. However, underprepared and vulnerable countries in sub-Saharan Africa and Central and South America might soon see substantial rises in COVID-19 cases and deaths, and concerted, collective action must be taken now to avoid catastrophe. There are many unknowns. The clinical and epidemiological interactions of COVID-19 with tuberculosis (with or without HIV) are likely to be highly complex. Simply put, tuberculosis transmission might rise because of increased respiratory symptoms associated with COVID-19, or decline owing to COVID-19-related self-isolation and quarantine. There is increasing recognition of the millions of people treated for tuberculosis who have residual, long-term lung damage who are likely to be at a higher risk of severe disease and death from COVID-19. Because of extreme pressures on health systems, exacerbated by COVID-19, people with tuberculosis are likely to face decreased access to diagnostic and treatment services, which might also result in adverse outcomes. Tuberculosis disproportionately affects men and boys compared with women and girls. Early data show that more men are dying from COVID-19, potentially due to sex-based immunological differences or gender-based factors such as prevalence of smoking. The association between COVID-19 and poverty is also unclear but, as more data become available, we will be able to better understand the differential effects of COVID-19 according to socioeconomic position. COVID-19, like tuberculosis, will almost certainly be associated with the medical poverty trap, in which poorer people have a higher likelihood of infection, disease, and adverse outcomes. Moreover, unemployed populations and informal or so-called zero-hours contract workers will experience further impoverishment, which increases risk of tuberculosis. Amid the expanding COVID-19 pandemic, our plea on World Tuberculosis Day is that we do not forget the tuberculosis pandemic, which, at present, is still the leading cause of infectious disease mortality. We need to continue to mobilise funding for research for better tuberculosis diagnostics, vaccine development, novel therapeutics, equitable access to care, and innovative social protection interventions for tuberculosis-affected households. We should drastically increase and sustain investment in health systems that are responsive to the needs of the poor and resilient to the threat of infections, especially those that are air-borne and require isolation facilities. We need to continue to inform, advocate for, and empower local communities and to lobby governments and policymakers to ensure that tuberculosis, as well as COVID-19, remain high on the global agenda. These two pandemics, one old and one new, remind us of the need to be proactive and long-sighted, to plan ahead, and to not become complacent.
  6 in total

1.  Tuberculosis among older adults--time to take notice.

Authors:  Joel Negin; Seye Abimbola; Ben J Marais
Journal:  Int J Infect Dis       Date:  2015-03       Impact factor: 3.623

2.  Patient outcomes associated with post-tuberculosis lung damage in Malawi: a prospective cohort study.

Authors:  Jamilah Meghji; Maia Lesosky; Elizabeth Joekes; Peter Banda; Jamie Rylance; Stephen Gordon; Joseph Jacob; Harmien Zonderland; Peter MacPherson; Elizabeth L Corbett; Kevin Mortimer; Stephen Bertel Squire
Journal:  Thorax       Date:  2020-02-26       Impact factor: 9.139

3.  Addressing social determinants to end tuberculosis.

Authors:  Tom Wingfield; Marco A Tovar; Sumona Datta; Matthew J Saunders; Carlton A Evans
Journal:  Lancet       Date:  2018-03-24       Impact factor: 79.321

4.  Preparedness and vulnerability of African countries against importations of COVID-19: a modelling study.

Authors:  Marius Gilbert; Giulia Pullano; Francesco Pinotti; Eugenio Valdano; Chiara Poletto; Pierre-Yves Boëlle; Eric D'Ortenzio; Yazdan Yazdanpanah; Serge Paul Eholie; Mathias Altmann; Bernardo Gutierrez; Moritz U G Kraemer; Vittoria Colizza
Journal:  Lancet       Date:  2020-02-20       Impact factor: 79.321

Review 5.  Sex Differences in Tuberculosis Burden and Notifications in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis.

Authors:  Katherine C Horton; Peter MacPherson; Rein M G J Houben; Richard G White; Elizabeth L Corbett
Journal:  PLoS Med       Date:  2016-09-06       Impact factor: 11.069

6.  COVID-19: the gendered impacts of the outbreak.

Authors:  Clare Wenham; Julia Smith; Rosemary Morgan
Journal:  Lancet       Date:  2020-03-06       Impact factor: 79.321

  6 in total
  15 in total

1.  Addressing the challenges of TB diagnosis in the COVID era.

Authors:  J Chikovore
Journal:  Public Health Action       Date:  2020-12-21

Review 2.  Anticipating the impact of the COVID-19 pandemic on TB patients and TB control programmes.

Authors:  Toyin Togun; Beate Kampmann; Neil Graham Stoker; Marc Lipman
Journal:  Ann Clin Microbiol Antimicrob       Date:  2020-05-23       Impact factor: 3.944

Review 3.  Severe COVID-19 and Sepsis: Immune Pathogenesis and Laboratory Markers.

Authors:  Mai M Zafer; Hadir A El-Mahallawy; Hossam M Ashour
Journal:  Microorganisms       Date:  2021-01-12

Review 4.  The potential impact of COVID-19-related disruption on tuberculosis burden.

Authors:  C Finn McQuaid; Nicky McCreesh; Jonathan M Read; Tom Sumner; Rein M G J Houben; Richard G White; Rebecca C Harris
Journal:  Eur Respir J       Date:  2020-08-13       Impact factor: 16.671

5.  The impact of the COVID-19 epidemic on tuberculosis control in China.

Authors:  Huang Fei; Xia Yinyin; Chen Hui; Wang Ni; Du Xin; Chen Wei; Li Tao; Huan Shitong; Sun Miaomiao; Chen Mingting; Salmaan Keshavjee; Zhao Yanlin; Daniel P Chin; Liu Jianjun
Journal:  Lancet Reg Health West Pac       Date:  2020-09-24

6.  Containment of COVID-19 in Ethiopia and implications for tuberculosis care and research.

Authors:  Hussen Mohammed; Lemessa Oljira; Kedir Teji Roba; Getnet Yimer; Abebaw Fekadu; Tsegahun Manyazewal
Journal:  Infect Dis Poverty       Date:  2020-09-16       Impact factor: 4.520

7.  Coping with COVID-19 in Sub-Saharan Africa: What Might the Future Hold?

Authors:  Franck J D Mennechet; Guy R Takoudjou Dzomo
Journal:  Virol Sin       Date:  2020-09-01       Impact factor: 4.327

8.  Tuberculosis, COVID-19, and the End Tuberculosis strategy in India.

Authors:  Digambar Behera
Journal:  Lung India       Date:  2020 Nov-Dec

Review 9.  The impact of COVID-19 on TB: a review of the data.

Authors:  C F McQuaid; A Vassall; T Cohen; K Fiekert; R G White
Journal:  Int J Tuberc Lung Dis       Date:  2021-06-01       Impact factor: 2.373

10.  It Ain't Over Till It's Over: The Triple Threat of COVID-19, TB, and HIV.

Authors:  Alexander W Kay; Tara E Ness; Leonardo Martinez; Anna M Mandalakas
Journal:  Am J Trop Med Hyg       Date:  2020-10       Impact factor: 3.707

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.